指南与共识类风湿关节炎

EULAR关于类风湿关节炎风险人群临床试验与观察性研究的考虑要点

EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis.
指南 / 共识 · Ann Rheum Dis · 2021-08-06

欧洲抗风湿病联盟(EULAR)工作组通过系统性文献综述制定共识,提出1项总体原则、10条考虑要点及研究议程,指导在类风湿关节炎(RA)风险人群中开展临床试验和观察性研究,涵盖风险人群定义、终点选择、风险因素评估和患者信息告知。

要点

  • 所有研究应测量流行病学和人口学特征,并按临床表现定义无症状、无关节炎的肌肉骨骼症状和早期临床关节炎三类风险人群。
  • 研究终点应包括影像学亚临床炎症、临床关节炎、RA发生及后续达到关节炎缓解。
  • 基线及适当随访时评估遗传标志、自身抗体谱,有症状或临床关节炎者还需评估临床症状和影像学亚临床炎症。

核心结论

  • EULAR共识为在RA风险人群中开展临床试验和观察性研究提供数据驱动的指导。

研究设计与样本

  • EULAR工作组提出四个研究问题,通过系统性文献综述结果形成共识声明,提出1项总体原则、10条考虑要点和研究议程。

主要发现

  • 所有在风险个体中开展的临床试验和研究应测量流行病学和人口学特征。
  • 按临床表现定义三类风险人群:无症状、无关节炎的肌肉骨骼症状和早期临床关节炎。
  • 研究终点应包括影像学亚临床炎症、临床关节炎、RA发生及后续达到关节炎缓解。
  • 基线及适当情况下重新评估风险因素,包括遗传标志和自身抗体谱,有症状和/或临床关节炎者还包括临床症状和影像学亚临床炎症。
  • 早期临床关节炎患者的药物干预具有预防RA发生的潜力。

关键数值与推荐

  • 工作组对每条考虑要点的同意程度进行1-10评分。
  • 试验应评估干预对风险因素的影响以及向临床关节炎或RA的进展。
  • 参与者对RA风险的了解可能影响其参与决定,应以个体化方式提供信息。

临床怎么用

  • 风湿科医生和研究人员可依据共识在RA风险人群中规范设计临床试验和观察性研究。
  • 研究应统一评估流行病学特征、定义风险人群亚型并选择包括影像学亚临床炎症和临床关节炎在内的终点。
  • 向参与者告知RA风险时应采用个体化方式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite growing interest, there is no guidance or consensus on how to conduct clinical trials and observational studies in populations at risk of rheumatoid arthritis (RA). METHODS: An European League Against Rheumatism (EULAR) task force formulated four research questions to be addressed by systematic literature review (SLR). The SLR results informed consensus statements. One overarching principle, 10 points to consider (PTC) and a research agenda were proposed. Task force members rated their level of agreement (1-10) for each PTC. RESULTS: Epidemiological and demographic characteristics should be measured in all clinical trials and studies in at-risk individuals. Different at-risk populations, identified according to clinical presentation, were defined: asymptomatic, musculoskeletal symptoms without arthritis and early clinical arthritis. Study end-points should include the development of subclinical inflammation on imaging, clinical arthritis, RA and subsequent achievement of arthritis remission. Risk factors should be assessed at baseline and re-evaluated where appropriate; they include genetic markers and autoantibody profiling and additionally clinical symptoms and subclinical inflammation on imaging in those with symptoms and/or clinical arthritis. Trials should address the effect of the intervention on risk factors, as well as progression to clinical arthritis or RA. In patients with early clinical arthritis, pharmacological intervention has the potential to prevent RA development. Participants' knowledge of their RA risk may inform their decision to participate; information should be provided using an individually tailored approach. CONCLUSION: These consensus statements provide data-driven guidance for rheumatologists, health professionals and investigators conducting clinical trials and observational studies in individuals at risk of RA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Mankia K, Siddle HJ, Kerschbaumer A, et al. EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. Ann Rheum Dis. 2021. PMID: 34362746. doi:10.1136/annrheumdis-2021-220884

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。